Mga Batayang Estadistika
| LEI | 529900NCBZHTTJV6HX73 |
| CIK | 1374690 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Larimar Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
General and Administrative Expenses UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIMAR TH |
|
| August 14, 2025 |
Larimar Therapeutics Reports Second Quarter 2025 Financial Results Exhibit 99.1 Larimar Therapeutics Reports Second Quarter 2025 Financial Results • Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025 • Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp clinical studies are currently screening and enrolling in the |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 14, 2025 |
pro August 2025 Larimar Therapeutics Corporate Deck Exhibit 99.2 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not l |
|
| July 31, 2025 |
Exhibit 1.1 18,750,000 Shares of Common Stock Larimar Therapeutics, Inc. UNDERWRITING AGREEMENT July 29, 2025 LEERINK PARTNERS LLC GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o GUGGENHEIM SECURITIES, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: Introductory. Lar |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commissio |
|
| July 31, 2025 |
18,750,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279275 PROSPECTUS SUPPLEMENT (To Prospectus dated May 24, 2024) 18,750,000 Shares of Common Stock We are offering 18,750,000 shares of our common stock. Deerfield Management Company, L.P., which we refer to as Deerfield Management, our largest stockholder, and/or certain of its affiliates, which we refer to collectively with D |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 Larimar Therapeutics, Inc. |
|
| July 29, 2025 |
SUBJECT TO COMPLETION, DATED JULY 29, 2025 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279275 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| June 23, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 23, 2025 |
Exhibit 99.1 Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program • Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA • Written FDA recommendations for safety database include a total of at least 30 participants with continuous |
|
| June 23, 2025 |
pro June 2025 Larimar Therapeutics Nomlabofusp Regulatory Update Exhibit 99.2 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, includ |
|
| June 23, 2025 |
pro June 2025 Larimar Therapeutics Corporate Deck Exhibit 99.1 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not lim |
|
| June 23, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 13, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 5, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2025 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 5, 2025 |
pro May 2025 Larimar Therapeutics Corporate Deck pro May 2025 Larimar Therapeutics Corporate Deck This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. |
|
| April 30, 2025 |
Larimar Therapeutics Reports First Quarter 2025 Financial Results Exhibit 99.1 Larimar Therapeutics Reports First Quarter 2025 Financial Results • FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval • BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025 • C |
|
| April 30, 2025 |
General and Administrative Expenses UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIMAR T |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 24, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Larimar Therapeutics, Inc. |
|
| March 24, 2025 |
pro March 2025 Larimar Therapeutics Corporate Deck Exhibit 99.2 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not li |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K t UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36510 LARIMAR THERA |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 24, 2025 |
Exhibit 99.1 Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results • FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval • FDA recommended measuring skin FXN concentrations to |
|
| March 24, 2025 |
LARIMAR THERAPEUTICS, INC. INSIDER TRADING POLICY Updated October 28, 2024 I. Purpose Larimar Therapeutics, Inc. (the “Company”) has adopted and updated this Insider Trading Policy (this “Policy”) to satisfy the Company’s obligation to prevent insider trading and to help the Company’s personnel and its external advisors avoid violating insider trading laws. II. Persons Subject to the Policy This P |
|
| March 24, 2025 |
GOODWIN PROCTER DRAFT: 2/15/2023 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER the larimar therapeutics, inc. |
|
| March 24, 2025 |
Subsidiaries of Larimar Therapeutics, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiary Ownership Percentage Jurisdiction of Incorporation or Organization Zafgen Australia Pty Ltd. 100% Australia |
|
| March 24, 2025 |
Power of Attorney (included on the signature page of this Registration Statement). S-8 As filed with the United States Securities and Exchange Commission on March 24, 2025 Registration No. |
|
| March 24, 2025 |
larimar therapeutics, inc. NON-QUALIFIED stock option grant notice and award agreement NON-PLAN INDUCEMENT AWARD Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) an non-qualified stock option to purchase the number of Shares set forth below (the “Option”). The Option is subject to the terms and conditions set forth in |
|
| January 27, 2025 |
LARIMAR THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to the Larimar Therapeutics, Inc. 2020 Equity Incentive Plan, as amended from time to time (the “Plan”) and this Performance-Based Restricted Stock Unit Award Agreement (this “Agreement”), Larimar Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants to the indi |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2025 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 10, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 10, 2025 |
pro January 2025 Larimar Therapeutics Corporate Deck Exhibit 99.1 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not |
|
| December 16, 2024 |
Exhibit 99.1 Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia • Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) study • Tissue frataxin (FXN) levels showed mean change fro |
|
| December 16, 2024 |
pro December 2024 Larimar Therapeutics Nomlabofusp Program Update Exhibit 99.2 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, inclu |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 18, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 18, 2024 |
November 2024 Larimar Therapeutics Corporate Deck Exhibit 99.1 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not lim |
|
| November 14, 2024 |
LRMR / Larimar Therapeutics, Inc. / Blue Owl Capital Holdings LP - SC 13G/A Passive Investment SC 13G/A 1 ef20038680sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 517125100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen |
|
| November 14, 2024 |
LRMR / Larimar Therapeutics, Inc. / Verition Fund Management LLC Passive Investment SC 13G/A 1 sadaveritionlarimarsc13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 517125100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stateme |
|
| October 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 30, 2024 |
October 2024 Larimar Therapeutics Corporate Deck Exhibit 99.2 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limi |
|
| October 30, 2024 |
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results • Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich’s ataxia (FA) receiving 25 mg of nomlabofusp daily for 30-180 days in ongoing open label extension (OLE) |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIM |
|
| August 8, 2024 |
CERTIFICATE OF AMENDMENT OF NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LARIMAR THERAPEUTICS, INC. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIMAR TH |
|
| August 7, 2024 |
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results Exhibit 99.1 Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results • Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024 • Selected by Food and Drug Administration (FDA) to participate in Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program for nomlabofusp • Joined TRACK-FA Neuroima |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2024 |
August 2024 Larimar Therapeutics Corporate Deck Exhibit 99.2 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (“Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limite |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 10, 2024 |
June 2024 Larimar Therapeutics Corporate Deck Exhibit 99.1 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 30, 2024 |
Exhibit 99.1 Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia • START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases • Nomlabofusp was selected based on potential for clinical benefit in a rare neurodegenerative disease and demonstrat |
|
| May 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 22, 2024 |
Larimar Therapeutics, Inc. Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania 19004 May 22, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Larimar Therapeutics, Inc. Registration Statement on Form S-3 Filed May 9, 2024 (File No. 333-279275) Ladies and Gentlemen: Pursuant to Ru |
|
| May 20, 2024 |
Exhibit 99.1 Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia • Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data • Ongoing open label extension (OLE) study initially evaluating 25 mg; Larimar plans to dose escalate to 50 mg following further characterization of |
|
| May 20, 2024 |
May 20 2024 Larimar Therapeutics Corporate Deck May 20 2024 Larimar Therapeutics Corporate Deck This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2024 |
Exhibit 1.2 LARIMAR THERAPEUTICS, INC. SALES AGREEMENT May 9, 2024 Guggenheim Securities, LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Guggenheim Securities, LLC (the “Agent”), as sales agent, shares o |
|
| May 9, 2024 |
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results Exhibit 99.1 Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results • First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 • Positive top-line Phase 2 dose exploration study data demonstrated nomlabofusp was generally well-tolerated with dose-dependent increases in tissue frataxin levels, reinforc |
|
| May 9, 2024 |
Form of Indenture (filed herewith). Exhibit 4.4 LARIMAR THERAPEUTICS, INC. INDENTURE Dated as of [ • ], 20[ • ] [ • ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 3 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series 4 Sectio |
|
| May 9, 2024 |
Sales Agreement, dated as of May 9, 2024, by and between the Company and Guggenheim Securities, LLC. LARIMAR THERAPEUTICS, INC. SALES AGREEMENT May 9, 2024 Guggenheim Securities, LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Guggenheim Securities, LLC (the “Agent”), as sales agent, shares of the Compan |
|
| May 9, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Larimar Therapeutics, Inc. |
|
| May 9, 2024 |
May 2024 Larimar Therapeutics Corporate Deck Exhibit 99.2 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIMAR T |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 12, 2024 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2024 |
LRMR / Larimar Therapeutics, Inc. / Flynn James E Activist Investment SC 13D/A 1 e619370sc13da-lt.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 9)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 517125100 (CUSIP Nu |
|
| March 14, 2024 |
LEASE between BALA PLAZA PROPERTY, INC., Landlord, and CHONDRIAL THERAPEUTICS, INC., a Delaware corporation, Tenant August 8, 2019 TABLE OF CONTENTS Page ARTICLE 1 BASIC LEASE PROVISIONS 1 ARTICLE 2 PREMISES, TERM, RENT 4 Section 2.1 Lease of Premises 4 Section 2.2 Commencement Date 4 Section 2.3 Payment of Rent 5 Section 2.4 First Month’s Rent 5 Section 2.5 Area of Premises and Building 5 ARTICLE |
|
| March 14, 2024 |
FIRST AMENDMENT TO LEASE This First Amendment to Lease (“Amendment”) is made as of this 9th day of March, 2023 (“Effective Date”) by and between Bala Plaza Property, Inc. |
|
| March 14, 2024 |
As filed with the United States Securities and Exchange Commission on March 14, 2024 As filed with the United States Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Larimar Therapeutics, Inc. |
|
| March 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 14, 2024 |
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development • Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in tissue frataxin levels observed • Initiated discussions with the Food and Drug Administration (FDA) on the poten |
|
| March 14, 2024 |
As filed with the United States Securities and Exchange Commission on March 14, 2024 As filed with the United States Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 14, 2024 |
Subsidiaries of Larimar Therapeutics, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiary Ownership Percentage Jurisdiction of Incorporation or Organization Zafgen Australia Pty Ltd. 100% Australia |
|
| March 14, 2024 |
GOODWIN PROCTER DRAFT: 2/15/2023 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER the larimar therapeutics, inc. |
|
| March 14, 2024 |
Larimar Therapeutics. Inc.’s Compensation Recovery Policy LARIMAR THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted as of September 21, 2023 Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted this Compensation Recovery Policy (this “Policy”) as described below. 1. Overview This Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons ( |
|
| March 14, 2024 |
Non-Qualified Stock Option Grant Notice and Award Agreement. larimar therapeutics, inc. NON-QUALIFIED stock option grant notice and award agreement NON-PLAN INDUCEMENT AWARD Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) an non-qualified stock option to purchase the number of Shares set forth below (the “Option”). The Option is subject to the terms and conditions set forth in |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K t UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36510 LARIMAR THERA |
|
| March 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Larimar Therapeutics, Inc. |
|
| March 11, 2024 |
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia • Study will inform on long-term safety profile and tissue frataxin levels • OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp • Frataxin data and safety data from the OLE study are intended to help support a potential Biologics License Application (“BLA”) submission for accelerated approval targeted for H2 2025 • Initial data expected in Q4 2024 Bala Cynwyd, PA, March 11, 2024 – Larimar Therapeutics, Inc. |
|
| March 11, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 11, 2024 |
March 2024 Larimar Therapeutics Corporate Deck March 2024 Larimar Therapeutics Corporate Deck This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. |
|
| March 11, 2024 |
March 13, 2024 Larimar Therapeutics Leerink Presentation Deck March 13, 2024 Larimar Therapeutics Leerink Presentation Deck This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. |
|
| February 26, 2024 |
LRMR / Larimar Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm247182d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 517125100 (CUSIP Number) February 16, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 16, 2024 |
LRMR / Larimar Therapeutics, Inc. / Flynn James E Activist Investment SC 13D/A 1 e619283sc13da-lt.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 8)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 517125100 (CUSIP Nu |
|
| February 16, 2024 |
Exhibit 1.1 17,162,472 Shares of Common Stock Larimar Therapeutics, Inc. UNDERWRITING AGREEMENT February 14, 2024 LEERINK PARTNERS LLC CITIGROUP GLOBAL MARKETS INC. GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o CITIGROUP GLOBAL MARKETS INC. 388 Greenwich Street New York, New York 10013 |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commi |
|
| February 15, 2024 |
LRMR / Larimar Therapeutics, Inc. / Flynn James E Activist Investment SC 13D/A 1 e619280sc13da-lt.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 7)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 517125100 (CUSIP Nu |
|
| February 15, 2024 |
EX-99.I 2 e619280ex99-i.htm Form of Lock-Up Agreement Leerink Partners LLC Citigroup Global Markets Inc. Guggenheim Securities, LLC As Representatives of the several Underwriters c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, |
|
| February 14, 2024 |
EX-99.1 2 d781817dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2024 |
LRMR / Larimar Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 517125 100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 14, 2024 |
LRMR / Larimar Therapeutics, Inc. / Blue Owl Capital Holdings LP - SC 13G Passive Investment SC 13G 1 ef20021760sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 14, 2024 |
LRMR / Larimar Therapeutics, Inc. / Verition Fund Management LLC - SC 13G Passive Investment SC 13G 1 ef20021522sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 14, 2024 |
17,162,472 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268312 PROSPECTUS SUPPLEMENT (To Prospectus dated November 21, 2022) 17,162,472 Shares of Common Stock We are offering 17,162,472 shares of our common stock. Deerfield Management Company, L.P., which we refer to as Deerfield Management, our largest stockholder, and/or certain of its affiliates, which we refer to collectively w |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 13, 2024 |
SUBJECT TO COMPLETION, DATED FEBRUARY 13, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268312 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| February 12, 2024 |
February 2024 Larimar Therapeutics Corporate Deck Exhibit 99.2 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not lim |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 12, 2024 |
February 2024 Larimar Therapeutics Nomlabofusp (CTI-1601) Program Update Exhibit 99. |
|
| February 12, 2024 |
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia • Nomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events • Dose dependent increases in frataxin levels were observed in skin and bu |
|
| November 14, 2023 |
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results • Completed full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during the dosing period, there were no serious adverse events in either the CTI-1601 (nomlabofusp) or placebo groups. • Top-line safety, pharmacokinetic, and |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIM |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2023 |
November 2023 Larimar Therapeutics Corporate Presentation Exhibit 99.2 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (“Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 Larimar Therapeutics, Inc. |
|
| August 14, 2023 |
August 2023 Larimar Therapeutics Corporate Presentation Exhibit 99.1 This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but n |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIMAR TH |
|
| August 10, 2023 |
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results • Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 data • Initiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 data • Top-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial’s 50 mg cohort expected in 1H 2024 • Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 • Cash, cash equivalents and marketable securities of $104. |
|
| August 10, 2023 |
EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made on May 23, 2023 by and between LARIMAR THERAPEUTICS, INC. |
|
| July 25, 2023 |
July 2023 Larimar Therapeutics CTI-1601 Program Update July 2023 Larimar Therapeutics CTI-1601 Program Update This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. |
|
| July 25, 2023 |
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial • Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024 • Initiation of open label extension trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 • Company management hosting a webcast and conference call today at 8:00 a. |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 17, 2023 |
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) - Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell “Rusty” Clayton, DO, as Chief Medical Officer (“CMO”), effective today. Dr. Cla |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2023 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 1, 2023 |
June 2023 Larimar Therapeutics Corporate Presentation June 2023 Larimar Therapeutics Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. |
|
| May 15, 2023 |
Exhibit 99.1 Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results • Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated when administered daily for 14 days and then every-other-day thereafter un |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIMAR T |
|
| May 15, 2023 |
May 2023 Larimar Therapeutics CTI-1601 Program Update Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking st |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 11, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commissio |
|
| March 17, 2023 |
LRMR / Larimar Therapeutics Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 6)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 517125100 (CUSIP Number) David Clark Elliot Press D |
|
| March 14, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Larimar Therapeutics, Inc. |
|
| March 14, 2023 |
Power of Attorney (included on the signature page of this Registration Statement) S-8 As filed with the United States Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
GOODWIN PROCTER DRAFT: 2/15/2023 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER the larimar therapeutics, inc. |
|
| March 14, 2023 |
EX-99.2 March 2023 Larimar Therapeutics Corporate Presentation Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-l |
|
| March 14, 2023 |
Subsidiaries of Larimar Therapeutics, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiary Ownership Percentage Jurisdiction of Incorporation or Organization Zafgen Australia Pty Ltd. 100% Australia |
|
| March 14, 2023 |
Power of Attorney (included on the signature page of this Registration Statement) S-8 1 d480314ds8.htm S-8 As filed with the United States Securities and Exchange Commission on March 14, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 LARIMAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-3857670 (State or other jurisdiction |
|
| March 14, 2023 |
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results EX-99.1 Exhibit 99.1 Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results • First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in participants with Friedreich’s ataxia (FA) is fully enrolled and proceeding as planned • Larimar expects to provide an update on the next steps of the Phase 2 trial in Q2 2023, after the FDA and independent dat |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commissi |
|
| March 14, 2023 |
EX-10 4 lrmr-ex1023.htm EX-10.23 DocuSign Envelope ID: EEF1D6D3-2768-4D08-A014-999612F16720 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. SECOND AMENDMENT TO MASTER SERVICES AGREEMENT This Second Amendment to the Maste |
|
| March 14, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Larimar Therapeutics, Inc. |
|
| March 14, 2023 |
larimar therapeutics, inc. NON-QUALIFIED stock option grant notice and award agreement NON-PLAN INDUCEMENT AWARD Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) an non-qualified stock option to purchase the number of Shares set forth below (the “Option”). The Option is subject to the terms and conditions set forth in |
|
| March 14, 2023 |
t UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36510 LARIMAR THERA |
|
| February 14, 2023 |
LRMR / Larimar Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 517125 100 (CUSIP Number) September 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 14, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC |
|
| February 13, 2023 |
LRMR / Larimar Therapeutics Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment SC 13G/A 1 lrmra221323.htm CHI ADVISORS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statem |
|
| February 7, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commis |
|
| February 7, 2023 |
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer Exhibit 99.1 Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer • Biologics expert and long-time veteran of Johnson & Johnson will be responsible for the strategic development of Larimar’s clinical and R&D programs Bala Cynwyd, PA, February 7, 2023 – Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatmen |
|
| January 23, 2023 |
LRMR / Larimar Therapeutics Inc / Opaleye Management Inc. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 517125100 (CUSIP Number) James Silverman, One Boston Place, 26th Fl. Boston MA 02108, 617-229-5085 (Name, Addr |
|
| January 9, 2023 |
January 2023 Larimar Therapeutics Corporate Presentation January 2023 Larimar Therapeutics Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 18, 2022 |
Larimar Therapeutics, Inc. Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania 19004 November 18, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Larimar Therapeutics, Inc. Registration Statement on Form S-3 Filed November 10, 2022 (File No. 333-268312) Ladies and Gentlemen: Pursuant to Rule 461 under |
|
| November 14, 2022 |
LRMR / Larimar Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* LARIMAR THERAPEUTICS, INC. (Name of Issuer) Common Shares, par value $0.001 per share (Title of Class of Securities) 517125100 (CUSIP Number) November 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| November 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Larimar Therapeutics, Inc. |
|
| November 10, 2022 |
Exhibit 4.3 LARIMAR THERAPEUTICS, INC. INDENTURE Dated as of [●], 20[●] [●] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 3 Section 1.3. Incorporation by Reference of Trust Indenture Act 3 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series 4 Section 2.2. |
|
| November 10, 2022 |
EX-1.2 2 d198548dex12.htm EX-1.2 Exhibit 1.2 LARIMAR THERAPEUTICS, INC. SALES AGREEMENT November 10, 2022 Guggenheim Securities, LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Guggenheim Securities, LLC |
|
| November 10, 2022 |
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results - First cohort of Larimar?s Phase 2 dose exploration trial of CTI-1601 in Friedreich?s ataxia patients is ongoing and proceeding in line with the Company?s planned timeline - Larimar expects to provide an update on the Phase 2 trial in Q2 2023 and anticipates reporting top-line data from both cohorts in 2H 2023 - Cash of $124. |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 10, 2022 |
November 2022 Larimar Therapeutics Corporate Presentation November 2022 Larimar Therapeutics Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIM |
|
| November 10, 2022 |
As filed with the Securities and Exchange Commission on November 10, 2022 Table of Contents As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| October 20, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 20, 2022 |
October 2022 Larimar Therapeutics Corporate Presentation October 2022 Larimar Therapeutics Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. |
|
| September 16, 2022 |
LRMR / Larimar Therapeutics Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13D-2(a) (Amendment No. 5)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 517125100 (CUSIP Number) David Clark Elliot Press D |
|
| September 16, 2022 |
JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the ?Exchange Act?) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with respect to securities of Larimar Therapeutics, Inc. |
|
| September 14, 2022 |
EX-99.1 Exhibit 99.1 Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients - Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 - Company management hosting webcast and conference call today at 8:30 a.m. ET Bala Cynwyd, PA, September 14, 2022 – Larimar The |
|
| September 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Comm |
|
| September 14, 2022 |
22,225,000 Shares of Common Stock 424B5 1 d372085d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-246370 PROSPECTUS SUPPLEMENT (To Prospectus dated September 1, 2020) 22,225,000 Shares of Common Stock We are offering 22,225,000 shares of our common stock. Deerfield Management Company, L.P., which we refer to as Deerfield Management, our largest stockholder, and/or certain of its affiliates, |
|
| September 14, 2022 |
EX-99.2 Exhibit 99.2 Larimar Therapeutics Corporate & Clinical Update September 14, 2022 1 Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statements contained in this presentation other than statements of historical fac |
|
| September 14, 2022 |
Exhibit 1.1 22,225,000 Shares of Common Stock LARIMAR THERAPEUTICS, INC. UNDERWRITING AGREEMENT September 14, 2022 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: Larimar Therapeutics, Inc., a corporation organized and existing under the laws |
|
| September 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 Larimar Therapeutics, Inc. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Larimar Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36510 20-3857670 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 11, 2022 |
IU Agreement No. 2022-0002 SECOND AMENDMENT TO LICENSE AGREEMENT This Second Amendment (the “Second Amendment”) is made and entered into as of May 28, 2020 (the “Second Amendment Effective Date”) by and between: The Trustees of Indiana University (“IU”), a body politic and corporate of the State of Indiana, having its principal offices at 107 S. Indiana Ave., Bloomington, IN 47405; and Larimar The |
|
| August 11, 2022 |
IU Agreement No. 2022-0109 THIRD AMENDMENT TO LICENSE AGREEMENT This Third Amendment (the “Third Amendment”) is made and entered into as of June 9, 2022 (the “Third Amendment Effective Date”) by and between: The Trustees of Indiana University (“IU”), a body politic and corporate of the State of Indiana, having its principal offices at 107 S. Indiana Ave., Bloomington, IN 47405; and Larimar Therape |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIMAR TH |
|
| August 11, 2022 | ||
| August 11, 2022 |
August 2022 Larimar Therapeutics Corporate Presentation Exhibit 99.2 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the ?Company?) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looki |
|
| August 11, 2022 |
Exhibit 99.1 Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results - Larimar plans to submit a complete response to CTI-1601?s clinical hold in the third quarter of 2022 - In conjunction with the complete response, Larimar is proposing a Phase 2, four-w |
|
| August 11, 2022 | ||
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Larimar Therapeutics, Inc. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIMAR T |
|
| May 12, 2022 |
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results Exhibit 99.1 Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results -CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022 - Cash at March 31, 2022 of $62.6 million provides projected cash runway into the third quarter of 2023 Bala Cynwyd, PA, May 12, 2022 ? Larimar |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2022 |
May 2022 Larimar Therapeutics Corporate Presentation Exhibit 99.2 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the ?Company?) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking |
|
| April 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commissio |
|
| March 25, 2022 |
Subsidiaries of Larimar Therapeutics, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiary Ownership Percentage Jurisdiction of Incorporation or Organization Zafgen Australia Pty Ltd. 100% Australia |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36510 LARIMAR THERAPE |
|
| March 25, 2022 |
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results Exhibit 99.1 Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results Bala Cynwyd, PA, March 25, 2022 ? Larimar Therapeutics, Inc. (?Larimar?) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its full year 2021 operating and financial results. ?The past year was highlighted by our |
|
| March 25, 2022 |
Exhibit 99.2 Larimar Therapeutics Corporate Presentation March 2022 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the ?Company?) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-look |
|
| March 25, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commissi |
|
| February 28, 2022 |
Exhibit 99.1 Larimar Therapeutics Corporate Presentation February 2022 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the ?Company?) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-l |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commi |
|
| February 18, 2022 |
LRMR / Larimar Therapeutics Inc / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 517125100 (CUSIP Number) James Silverman, One Boston Place, 26th Fl. Boston MA 02108, 617-229-5085 (Name, Address and Telephone Number of P |
|
| February 15, 2022 |
LRMR / Larimar Therapeutics Inc / ACUTA CAPITAL PARTNERS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Larimar Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2022 |
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program Exhibit 99.1 Larimar Therapeutics Provides Update on CTI-1601 Clinical Program Bala Cynwyd, PA, February 14, 2022 ? Larimar Therapeutics, Inc. (?Larimar?) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on Lari |
|
| February 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commi |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* LARIMAR THERAPEUTICS, INC. (Name of Issuer) Common Shares, par value $0.001 per share (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 11, 2022 |
LRMR / Larimar Therapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 11, 2022 |
CUSIP No. 517125100 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, par value $0.001 per share, of Larimar Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the |
|
| February 11, 2022 |
LRMR / Larimar Therapeutics Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 12, 2021 |
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results Bala Cynwyd, PA, November 12, 2021 ? Larimar Therapeutics, Inc. (?Larimar?) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter and year to date September 30, 2021 operating and financial results. ?We are advanc |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36510 LARIM |
|
| November 12, 2021 |
Exhibit 99.2 Larimar Therapeutics Corporate Presentation November 2021 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the ?Company?) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-l |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commi |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36510 LARIMAR THE |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commiss |
|
| August 12, 2021 |
August 2021 Larimar Therapeutics Corporate Presentation Exhibit 99.2 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the ?Company?) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looki |
|
| August 12, 2021 |
Exhibit 99.1 Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results - Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreich?s ataxia (FA) - Subcutaneous injections of CTI-1601 at doses of 50 mg or 100 mg resulted in frataxin levels in buccal cells of FA patients that were at or in excess of those tha |
|
| July 2, 2021 |
LRMR / Larimar Therapeutics Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13D-2(a) (Amendment No. 3)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 517125100 (CUSIP Number) David Clark Elliot Press D |
|
| July 1, 2021 |
Exhibit 99.1 Larimar Therapeutics Corporate Presentation July 2021 1Exhibit 99.1 Larimar Therapeutics Corporate Presentation July 2021 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the ?Company?) and on information currently available to management. All statements contained in this pre |
|
| July 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commission |
|
| June 14, 2021 |
Exhibit 99.1 Larimar Therapeutics Corporate Presentation June 2021 1Exhibit 99.1 Larimar Therapeutics Corporate Presentation June 2021 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the ?Company?) and on information currently available to management. All statements contained in this pre |
|
| June 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commissio |
|
| May 26, 2021 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commission |
|
| May 26, 2021 |
Exhibit 99.1 Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing Bala Cynwyd, PA, May 25, 2021 ? Larimar Therapeutics, Inc. (?Larimar?) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich?s ataxia (FA) and other complex rare diseases, today announced that the United States Fo |
|
| May 26, 2021 |
LRMR / Larimar Therapeutics Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13D-2(a) (Amendment No. 3)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 517125100 (CUSIP Number) David Clark Elliot Press D |
|
| May 21, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of May 20, 2021, by and among Larimar Therapeutics, Inc., a Delaware corporation, with headquarters located at Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004 (the ?Company?), and the investors listed on the Schedule of Investors attached hereto (individually, an ?Investor? and collectivel |
|
| May 21, 2021 |
Exhibit 10.3 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of May 25, 2021 (the ?Effective Date?), is made and entered into by and among Larimar Therapeutics, Inc., a Delaware corporation (the ?Company?), and each of the investors set forth on the signature pages hereto (each, including each Person that becom |
|
| May 21, 2021 |
Exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED (OTHER THAN IN THE ORDINARY COURSE OF BUSINESS AS PART OF MARGIN OR PRIME BROKERAGE ARRANGEMENTS), HYPOTHECATED, TRANSFERRED OR ASSIGNE |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commission |
|
| May 21, 2021 |
Exhibit 99.1 Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich?s Ataxia Bala Cynwyd, PA, May 20, 2021 ? Larimar Therapeutics, Inc. (?Larimar?) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich?s ataxia (FA) and other complex rare diseases, today announced that the European M |
|
| May 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commission |
|
| May 21, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 2)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 517125100 (CUSIP Number) David Clark Elliot Press D |
|
| May 21, 2021 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of May 25, 2021 (the ?Effective Date?), is made and entered into by and among Larimar Therapeutics, Inc., a Delaware corporation (the ?Company?), and the ?Investors? named in that certain Securities Purchase Agreement, dated as of May 20, 2021, by and among the Company and the Investors (the |
|
| May 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commission |
|
| May 18, 2021 |
May 2021 Larimar Therapeutics Corporate Presentation Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the ?Company?) and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking |
|
| May 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 Larimar Therapeutics, Inc. |
|
| May 11, 2021 |
Exhibit 99.2 Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich?s Ataxia - Data demonstrate proof-of-concept by showing that daily subcutaneous injections of CTI-1601 for up to 13 days resulted in dose-dependent increases in frataxin levels from baseline compared to placebo in all evaluated tissu |
|
| May 11, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2021 |
May 11, 2021 Larimar Therapeutics Phase 1 Topline Data Conference Call Exhibit 99. |
|
| May 10, 2021 |
Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. FIRST AMENDMENT TO MASTER SERVICES AGREEMENT This First Amendment to the Master Services Agreement (?First Amendment?) executed as of the dates below and effec |
|
| May 10, 2021 |
Exhibit 99.1 Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results - Topline data from placebo-controlled Phase 1 program in Friedreich?s ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 Bala Cynwyd, PA, May 10, 2021 ? Larimar Therapeut |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36510 LARIMAR TH |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Larimar Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36510 20-3857670 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2021 |
Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. Master Services Agreement This Master Services Agreement (this ?Agreement?) dated September 20, 2017 (the ?Effective Date?), between Chondrial Therapeutics, In |
|
| April 14, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| March 4, 2021 |
Exhibit 99.1 Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results - Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich?s ataxia (FA) patients - Placebo-controlled Phase 1 trials in FA patients remain on track for topli |
|
| March 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 Larimar Therapeutics, Inc. |
|
| March 4, 2021 |
Exhibit 4.2 DESCRIPTION OF THE COMPANY?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Larimar Therapeutics, Inc., or the Company, has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The Company?s common stock, $0.001 par value per share, or the Common Stock, is registered under Secti |
|
| March 4, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| March 4, 2021 |
Subsidiaries of Larimar Therapeutics, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiary Ownership Percentage Jurisdiction of Incorporation or Organization Zafgen Australia Pty Ltd. 100% Australia Chondrial Therapeutics IP, LLC 100% Delaware Zafgen Securities Corp. 100% Massachusetts Zafgen Animal Health, LLC 100% Delaware |
|
| March 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36510 LARIMAR THERAPE |
|
| March 4, 2021 |
UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS On December 17, 2019, Zafgen, Inc. (?Zafgen?), Chondrial Therapeutics Inc. (?Chondrial?), Zordich Merger Sub, Inc. (?Merger Sub?) and Chondrial Holdings, LLC (?Holdings?), the sole stockholder of Chondrial, entered into an Agreement and Plan of Merger, as amended on March 9, 2020 (the ?Merger Agreement?), pursuant to which Merger Sub m |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 517125100 (CUSIP Number) February 4, 20211 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* Larimar Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2020 (Date of Even |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Larimar Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 517125100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ |
